English

OxySure (OXYS) 3Q15 Results - 14 Consecutive Growth Quarters - Video News Alert on InvestmentPitch.com

Report this content

Vancouver, British Columbia-- (Marketwired - November 20, 2015) - Medical device innovator, OxySure Systems (OTCQB: OXYS) announced results for the 3rd quarter 2015, reporting 14 consecutive quarters of growth.

InvestmentPitch.com has produced a "video news alert" which discusses the company’s financial results. If this link is not enabled, please visit www.InvestmentPitch.com and enter "OxySure" in the search box.

If you cannot view the video above, please visit: http://www.investmentpitch.com/#sthash.d3I1QixO.dpuf

Julian T. Ross, Chairman and CEO of OxySure stated: "This has been a good building quarter for us. We were able to bring strong management to the opportunities and challenges along the way and we are pleased with the exemplary results."

OxySure pioneered a safe and easy to use solution to produce medically pure oxygen from two dry, inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products.

3Q 2015 Results Highlights Included:

• Total revenue up 39% to $1,138,380 (3 months)

• Total revenue up 52% to $2,809,553 (9 months)

• Gross profit up 12% to $558,254 (3 months)

• Gross profit up 40% to $1,484,388 (9 months)

• Total cash up 210% to $2,006,312 at September 30, 2015 from $647,093 at December 31, 2014

• Working capital surplus up 253% to $1,479,075 at September 30, 2015 from $418,734 at December 31, 2014

• Total assets up 76% to $4,424,003 at September 30, 2015 from $2,511,448 at December 31, 2014

• Stockholder equity up 103% to $2,180,918 at September 30, 2015 from $1,074,788 at December 31, 2014.

• TTM revenue $3.4 million

• Revenue run rate approaching $5 million

• On track for revenue run rate of $10 million in 2016

• On track for breakeven in 2016

When asked about future plans, Ross stated: “Looking forward, we remain on track with the launch of at least one new solution in 2015,” added Ross. “Also, we have started working with our medical advisors on laying the ground work for our direct to consumer campaign addressing “At Risk” markets such as Asthma and Immunology markets. We expect to continue our efforts to grow our direct sales force. We have made additional progress and will be continuing our work on the Nasdaq uplisting process. Finally, our growth plan is working and our investments are paying dividends. We are especially excited about working towards one of our next key milestones, which is to reach the $10 million revenue run rate number and breakeven some time in 2016.”

For more information, please visit the company's website www.oxysure.com.

In Canada, investor relations is handled by Bettina Filippone of Renmark Financial Communications, who can be reached at bfilippone@renmarkfinancial.com.  In the US, please contact Jon Cunningham at Redchip Companies, who can be reached at jon@redchip.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:

InvestmentPitch.com

Barry Morgan, CFO

bmorgan@investmentpitch.com

Tags:

safety Special Olympics CDC EMS oxygen penny stocks respiratory UAV UAS OXYS growth stock oxygen deprivation medical supplies first aid lay rescuer medical emergency safety oxygen Drones penny stock hot stock stock lifesaving wall cabinet wallbox Ebola Drone blood warmer IV Fluid Infusion intravenous Cramer best stock Cramer stock pick Medical technology stocks Fda medical device approval Fda approval for medical devices penny stock picks best penny stocks stocks to buy now stock picks stocks to buy top stocks jim cramer picks cramer stocks jim cramer stock pick top penny stocks penny stocks to watch mad money stock picks warren buffett stock picks

Documents & Links

Quick facts

3Q 2015 Results Highlights Included: • Total revenue up 39% to $1,138,380 (3 months) • Total revenue up 52% to $2,809,553 (9 months) • Gross profit up 12% to $558,254 (3 months) • Gross profit up 40% to $1,484,388 (9 months) • Total cash up 210% to $2,006,312 at September 30, 2015 from $647,093 at December 31, 2014 • Working capital surplus up 253% to $1,479,075 at September 30, 2015 from $418,734 at December 31, 2014 • Total assets up 76% to $4,424,003 at September 30, 2015 from $2,511,448 at December 31, 2014 • Stockholder equity up 103% to $2,180,918 at September 30, 2015 from $1,074,788 at December 31, 2014. • TTM revenue $3.4 million • Revenue run rate approaching $5 million • On track for revenue run rate of $10 million in 2016 • On track for breakeven in 2016
Tweet this

Quotes

This has been a good building quarter for us. We were able to bring strong management to the opportunities and challenges along the way and we are pleased with the exemplary results.
Julian T. Ross, CEO
Looking forward, we remain on track with the launch of at least one new solution in 2015,” added Ross. “Also, we have started working with our medical advisors on laying the ground work for our direct to consumer campaign addressing “At Risk” markets such as Asthma and Immunology markets.
Julian T. Ross, CEO
We expect to continue our efforts to grow our direct sales force. We have made additional progress and will be continuing our work on the Nasdaq uplisting process. Finally, our growth plan is working and our investments are paying dividends. We are especially excited about working towards one of our next key milestones, which is to reach the $10 million revenue run rate number and break even some time in 2016.
Julian T. Ross, CEO